These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24118041)

  • 1. Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands.
    Vauquelin G; Bricca G; Van Liefde I
    Fundam Clin Pharmacol; 2014 Oct; 28(5):530-43. PubMed ID: 24118041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.
    Vauquelin G
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):949-62. PubMed ID: 23812645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.
    Vauquelin G; Charlton SJ
    Br J Pharmacol; 2013 Apr; 168(8):1771-85. PubMed ID: 23330947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs.
    Valant C; Sexton PM; Christopoulos A
    Mol Interv; 2009 Jun; 9(3):125-35. PubMed ID: 19592673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bivalent and bitopic ligands of the opioid receptors: The prospects of a dual approach.
    Hovah ME; Holzgrabe U
    Med Res Rev; 2024 May; ():. PubMed ID: 38751227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors.
    Valant C; Robert Lane J; Sexton PM; Christopoulos A
    Annu Rev Pharmacol Toxicol; 2012; 52():153-78. PubMed ID: 21910627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of kinetics by cooperative interactions.
    Hellmann N
    IUBMB Life; 2011 May; 63(5):329-36. PubMed ID: 21491560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric binding cooperativity in a kinetic context.
    Díaz Ó; Martín V; Renault P; Romero D; Guillamon A; Giraldo J
    Drug Discov Today; 2023 Feb; 28(2):103441. PubMed ID: 36372329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration of the orthosteric/allosteric interface in human M1 muscarinic receptors by bitopic fluorescent ligands.
    Daval SB; Kellenberger E; Bonnet D; Utard V; Galzi JL; Ilien B
    Mol Pharmacol; 2013 Jul; 84(1):71-85. PubMed ID: 23604140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bridging the gap: bitopic ligands of G-protein-coupled receptors.
    Lane JR; Sexton PM; Christopoulos A
    Trends Pharmacol Sci; 2013 Jan; 34(1):59-66. PubMed ID: 23177916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor.
    Guo D; Venhorst SN; Massink A; van Veldhoven JP; Vauquelin G; IJzerman AP; Heitman LH
    Br J Pharmacol; 2014 Dec; 171(23):5295-312. PubMed ID: 25040887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.
    Tränkle C; Weyand O; Voigtländer U; Mynett A; Lazareno S; Birdsall NJ; Mohr K
    Mol Pharmacol; 2003 Jul; 64(1):180-90. PubMed ID: 12815174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. gamma-Aminobutyric acid receptor binding in fresh mouse brain membranes at 22 degrees C: ligand-induced changes in affinity.
    Yang JS; Olsen RW
    Mol Pharmacol; 1987 Aug; 32(1):266-77. PubMed ID: 3039341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors.
    Lazareno S; Birdsall NJ
    Mol Pharmacol; 1995 Aug; 48(2):362-78. PubMed ID: 7651370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing the Existence of a Metastable Binding Site at the β
    Gaiser BI; Danielsen M; Marcher-Rørsted E; Røpke Jørgensen K; Wróbel TM; Frykman M; Johansson H; Bräuner-Osborne H; Gloriam DE; Mathiesen JM; Sejer Pedersen D
    J Med Chem; 2019 Sep; 62(17):7806-7839. PubMed ID: 31298548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems.
    Vauquelin G; Van Liefde I
    Expert Opin Drug Discov; 2012 Jul; 7(7):583-95. PubMed ID: 22650795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized muscarinic toxin 7.
    Fruchart-Gaillard C; Mourier G; Marquer C; Ménez A; Servent D
    Mol Pharmacol; 2006 May; 69(5):1641-51. PubMed ID: 16439611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic analysis of high affinity forms of interleukin (IL)-13 receptors: suppression of IL-13 binding by IL-2 receptor gamma chain.
    Kuznetsov VA; Puri RK
    Biophys J; 1999 Jul; 77(1):154-72. PubMed ID: 10388747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calculation of cooperativity and equilibrium constants of ligands binding to G-quadruplex DNA in solution.
    Kudrev AG
    Talanta; 2013 Nov; 116():541-7. PubMed ID: 24148442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of rigid or flexible linkage between two ligands on the effective affinity and avidity for reversible interactions with bivalent receptors.
    Bobrovnik SA
    J Mol Recognit; 2007; 20(4):253-62. PubMed ID: 17847051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.